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times in delivery accumulate with increasing number of 
rescans for all discrete scanning techniques, especially for 
spot scanning. Thus, efficient rescanning requires fast lateral 
scanning; yet the flexibility to deliver highly modulated fields 
must be preserved. For this purpose, we pursue the 
implementation of a novel delivery technique, in which we 
scan the beam continuously along straight lines while quickly 
modulating the scan speed and/or beam current to shape the 
dose profile [3]. 
Method: Our Gantry 2 beamline provides the necessary 
prerequisites for this technique: (a) the extracted cyclotron 
current can be adjusted in less than 1 ms [4] and (b) the 
proton beam can be scanned with up to 2 cm/ms in lateral 
direction [5]. Thus, the frequency of speed and current 
modulation along a line can be remarkably high, which allows 
us to deliver both uniform and highly modulated fields. To do 
so, we divide each iso-energy layer in parallel lines and each 
of those lines in small segments (sub-mm resolution). The 
planned dose profile defines the scan speed and beam 
current of each segment. Since delivery accuracy strongly 
depends on the stability of the beam current, we installed a 
feedback system, in which the current measured in the 
gantry nozzle controls the output of the cyclotron in real-
time. 
Results: We found that scan speed modulation is favorable 
over beam current modulation for two reasons: (1) accuracy – 
we can control the scanner magnets with higher precision 
and shorter response time than the extracted cyclotron 
current – and (2) efficiency –  scanning lines with a high 
current minimizes the overall beam-on time. Thus, the beam 
current is set to its maximum and lowered only in regions, 
where pure speed modulation fails to decrease the delivered 
dose sufficiently. This preserves full flexibility on dose 
modulation. We verified this approach by comparing highly 
modulated dose profiles delivered with both spot and line 
scanning (cf. figure 1). While the lateral penumbra of the 
line scan is slightly worse (less than + 0.1 mm on both sides), 
its delivery time is 20% smaller. We expect the reduction in 
delivery time to be even larger when rescanning multiple 
times. 
Conclusion: Line scanning is a fast scanning technique that 
offers the possibility to deliver arbitrary dose distributions by 
quickly modulating the scan speed and beam current. Thus, 
we consider line scanning a well-suited technique to realize 
efficient and accurate rescanning of moving tumors. 
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Cancer treatment in hadron therapy facilities equipped with 
pencil beam scanning (PBS) is based on delivering each 
energy layer,  spot by spot in the plane perpendicular to the 
beam axis. Uniform and robust treatment plan depends on 
the correct values defining horizontal and vertical spot size 
(i.e. σx, σy) introduced to the Treatment Planning System 
(TPS) like Eclipse (Varian). In  TPS these values are, however, 
assumed to be constant for a given layer, moreover the 
influence of the spot rotation on the spot dimensions is not 
taken into account (Fig.). The purpose of this study was to 
propose criteria of spot asymmetry within which target dose 
conformity is preserved. 
In the Eclipse for Proton TPS a conformal field of 
3 x 3 x 3 cm3 was planned to cover the whole target volume 
with at least 95% dose. A dedicated tool was developed to 
convert the treatment plan into the simulation input file.  
Simulations were performed with FLUKA transport code [1,2] 
with uncertainty level kept below 1%, by using computational 
PL-Grid Infrastructure. 
Dedicated beam model for proton scanning beam in the 
gantry-1 room at the Bronowice Cyclotron Centre (IFJ 
Kraków) was used. Preserving the 2D Gaussian spot shape 
(volume integral) and spot weight, spot σ up to 50% and spot 
rotation up to 45° were investigated. 1D and 2D analysis of 
dose distribution was carried out. 
For asymmetrical spots field width differences were observed 
together with larger lateral penumbra (the factor of 1.5 
obtained for maximal spot asymmetry), which resulted in 
target volume decrease [3]. Perturbed field flatness did not 
exceed the accepted level of 5% difference. By spot rotation 
implemented to all spots whole target region skewness was 
observed. 
The tool for treatment plan conversion into a Monte Carlo 
input file has been created to consider spot deformation 
indistinct to the TPS dose calculation. Observed field dose 
non-uniformity may be the origin of hot and cold spots inside 
and outside the target volume. Considered spot asymmetry 
criteria allow to preserve optimal target dose distribution 
with regard to the spot size changes. As such spot 
deformation can differ for different gantry angles, accurate 
gantry-angle-dependent spot shape measurements with 2D 
detectors such as films or 2D foils are considered. 
 
S58  ICTR-PHE 2016 
 
 
Keywords: proton radiotherapy, spot asymmetry, Monte Carlo 
 
References: 
[1] V. Bohlen, et al., Nuclear Data Sheets 120, 211-214 (2014) 
[2] A. Ferrari, et al., CERN-2005-10, INFN/TC_05/11, SLAC-R-
773 (2005) 
[3] K. Parodi, et al., Phys. Med. Biol. 55 (2010) 5169–5187 
 
119 
191Os – revival of an out-of-favor radionuclide? 
U. Köster1, B. Lee2,  
1 Institut Laue-Langevin, Grenoble, France 
2 Australian National University, Canberra, Australia 
 
Purpose: Novel osmium anticancer drugs are under evaluation 
that promise superior properties with respect to traditional 
Pt based drugs [1]. Even selective action against cancer stem 
cells has been reported [2]. Radiotracer and nuclear 
medicine techniques could help in the development and 
application of these drugs. 191Os is an osmium radioisotope 
well suited for this purpose with excellent properties for 
imaging and therapy. We discuss calculated Auger electron 
spectra, production methods and prospects of applications of 
191Os. 
Methods: 191Os (T1/2=15.4 d) decays to short-lived (T1/2=4.9 s) 
191mIr that emits 129 keV γ rays (26.5% intensity) well suited 
for SPECT imaging. In the past 191Os/191mIr generators [3] were 
used to provide 191mIr for first pass radionuclide 
angiocardiography [4] or studies of renal blood flow [5], but 
no direct use of 191Os has been reported so far. Among all 
known β-emitters with days to weeks half-life 191Os sticks up 
with the lowest β decay energy of only 38 keV on average 
(114 keV maximum), corresponding to a range of about one 
cell diameter. This β radiation is supplemented by abundant 
emission of short-range conversion and Auger electrons (< 60 
keV). Consequently 191Os has also potential as therapeutic 
isotope. The Auger electron spectrum of this decay was 
calculated using the methodology described in Ref. [6]. 
Results: The figure shows the calculated electron energy 
spectrum in the β- decay of 191Os (red, left scale) and in the 
internal transition decay of 191mIr (blue and yellow, right 
scale). 
 
 
Upon β- decay of 191Os the nuclear recoil of 191mIr is <0.4 eV, 
thus avoiding breakage of chemical bonds and uncontrolled 
translocation of 191mIr, provided the chemical valency change 
is tolerated. 
Direct production by 190Os(n,γ)191Os in a high thermal neutron 
flux of 1.5⋅1015 n.cm-2s-1 in ILL’s high flux reactor [7] reaches 
specific activities of ≈10 GBq/mg (≈2 MBq/µmol) after 5 days 
of irradiation. 
For Os drug dosages similar to cisplatin dosage this specific 
activity is by far sufficient for preclinical and clinical SPECT 
imaging. Even shorter irradiation times can be used to 
minimize co-produced activities (192Ir, etc.). 
Conclusions: Reactor-produced 191Os has great potential as 
radiotracer for in vitro studies of sub-cellular distribution of 
Os based drugs, for preclinical and clinical in vivo studies of 
pharmacokinetics of Os based drugs and eventually even for 
combined radionuclide-chemotherapy against particularly 
resistant tumors. 
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In 1999 to 2011, 249 cancer patients received 
boronophenylalanine (BPA)-mediated boron neutron capture 
therapy (BNCT) in Finland. Over one hundred of these 
patients were treated within the context of clinical trials. 
The purpose of the trials was to investigate the efficacy and 
safety of BNCT in the treatment of malignant gliomas (newly 
diagnosed or gliomas that progressed after surgery and 
radiotherapy) [1,2], and inoperable head-and-neck cancers 
that had recurred locally after external radiotherapy [3,4]. 
In BNCT, the absorbed radiation dose results from four main 
components: 1) the therapeutically desired high-LET 
